HELP logo

HELP Helus Pharma Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$6.11
-0.67 (-9.88%)

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety di…

Market Cap: $378.72Mwww.helus.com

Price

No data yet.

Social Signal Score

51
5d
—
30d
53
3 mentions
—
60d
50
6 mentions
—
90d
50
7 mentions
—
news: 7

Analyst Ratings

5 analysts
Buyconsensus
Strong Buy 0Buy 5Hold 0Sell 0Strong Sell 0
Avg price target$22+260.1%
Low $15Median $16High $35
Current Consensus

Revenue

$0.00
$0.00$288.0K$576.0K$864.0K
Oct 2017Sep 2026

Analyst Estimates

FY2026
$-4.03
$-4.48–$-3.59
4 analysts
FY2027
$-3.18
$-3.81–$-2.42
4 analysts
FY2028
$-2.37
$-2.54–$-2.20
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Michael I. Halstead
Sector
Healthcare
Industry
Biotechnology
Employees
100
Beta
0.54
Country
CA
Piotroski score
3 / 9 (Weak)
Altman Z-score
15.12
www.helus.com